Exited position

Seth Klarman’s Nuvation Bio Inc (NUVB) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Baupost GroupVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ1 2021Earliest verified positive filing snapshot
Latest statusExited positionBased on the latest supported relationship state
Peak shares10.44MHighest verified quarter-end share count
Quarters reported8Verified quarters with shares above zero
What happened?

Baupost Group first reported Nuvation Bio Inc in Q1 2021. The reported position was increased and reduced across later filings. The latest verified relationship event shows that Baupost Group sold the entire position in Q1 2023, and the stock is no longer reported in the latest verified portfolio.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q1 2023
Sold the entire position−4.81M shares · No shares reported at quarter-end
Q4 2022
Sold 53.8% of the position−5.61M shares · 4.81M shares remained
Filing context

Quarter-end price $1.92 · Estimated holding basis $8.81

Q2 2022
Sold 0.2% of the position−25.30K shares · 10.42M shares remained
Filing context

Quarter-end price $3.24 · Estimated holding basis $8.81

Q1 2022
Bought 21.1% more+1.82M shares · 10.44M shares reported after the change
Filing context

Quarter-end price $5.26 · Estimated holding basis $8.81

Q1 2021
New position+8.62M shares · 8.62M shares reported
Filing context

Quarter-end price $9.55 · Estimated holding basis $9.55

4 unchanged quarters are collapsed by default.

Portfolio importance

How important was Nuvation Bio Inc in Baupost Group’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Last reported portfolio weight0.2%Q4 2022
Last reported rank#29of 34 reported positions
Peak portfolio weight0.8%Q3 2021
Best historical rank#25Q4 2021
At peak importanceQ3 2021
NUVB
0.8%
Largest holding
14.6%
Cross-investor discovery

Who else owns Nuvation Bio Inc?

Also reported by 4 other tracked investors in their latest verified filings.

Stanley DruckenmillerDuquesne Family Office
NUVB0.6% of reported portfolio
David AbramsAbrams Capital Management, L.P.
NUVB0.1% of reported portfolio
David EinhornDME Capital Management
NUVB0.0% of reported portfolio
Explore Nuvation Bio Inc across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$5.852026-09-18

Market context only; not an investor transaction price.

Latest verified investor filingQ2 2026 · filed 2026-08-13
Open SEC filing ↗

This tracker follows Baupost Group LLC/MA’s Form 13F disclosures—not Seth Klarman’s personal brokerage account. Form 13F reports quarter-end U.S.-listed positions and certain options, but it does not reveal exact trade dates, execution prices, short positions or the purpose of an option position.